Sotuletinib (BLZ945) is an experimental drug in development for the treatment of
amyotrophic lateral sclerosis (ALS). It works as a colony-stimulating factor 1 (
CSF1) receptor inhibitor.[1][2][3]
^Martinez-Gonzalez, Loreto; Martinez, Ana (1 February 2023). "Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 32 (2): 141–160.
doi:
10.1080/13543784.2023.2178416.
hdl:10261/308825.
PMID36762798.
Sotuletinib (BLZ945) is an experimental drug in development for the treatment of
amyotrophic lateral sclerosis (ALS). It works as a colony-stimulating factor 1 (
CSF1) receptor inhibitor.[1][2][3]
^Martinez-Gonzalez, Loreto; Martinez, Ana (1 February 2023). "Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis". Expert Opinion on Investigational Drugs. 32 (2): 141–160.
doi:
10.1080/13543784.2023.2178416.
hdl:10261/308825.
PMID36762798.